EMEA-001784-PIP01-15-M04
Key facts
| Invented name |
Beyfortus
|
| Active substance |
Nirsevimab
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0296/2021
|
| PIP number |
EMEA-001784-PIP01-15-M04
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Prevention of lower respiratory tract disease caused by respiratory syncytial virus
|
| Route(s) of administration |
Intramuscular use
|
| Contact for public enquiries |
AstraZeneca AB
Tel. +46 855259283 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|